je.st
news
Tag: combination
Brazilian Waiting Period Expires for ARRIS-Pace Combination
2015-12-22 23:28:30| Telecom - Topix.net
As a result, all merger control closing conditions worldwide have now been met. The previously issued court order regarding the scheme of arrangement governing the acquisition of Pace plc will be delivered to the U.K. Registrar of Companies on About ARRIS ARRIS Group Inc. is a world leader in entertainment and communications technology.
Tags: period
combination
waiting
brazilian
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA (pembrolizumab) Combination Trial
2015-12-10 12:30:08| Merck.com - Product News
Dateline City: INDIANAPOLIS and KENILWORTH, N.J. INDIANAPOLIS and KENILWORTH, N.J. Eli Lilly and Company (NYSE: LLY) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lillys cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Mercks KEYTRUDA (pembrolizumab) in a Phase I study across multiple tumor types. Language: English read more
Tags: trial
combination
expand
adding
CP responds to Norfolk Southern's rejection of proposed combination
2015-12-05 19:06:59| Railroads - Topix.net
CP takes exception to the claims, misdirection and mischaracterization of its offer and the benefits such a combination would provide to customers, shareholders, the industry and the public. to discuss our offer and deliver clarity, context and detail to the proposed transaction.
Tags: combination
proposed
norfolk
rejection
CF Industries And OCI Committed To Pursuing Combination
2015-11-30 07:19:00| pollutiononline Home Page
CF Industries Holdings, Inc. and OCI N.V. recently announced that both companies remain fully committed to pursuing a combination of CF with OCI’s European, North American and global distribution businesses due to its strong industrial logic, significant expected synergies and value creation potential for shareholders
Tags: combination
industries
committed
pursuing
GSK and Merck to Study Immunotherapy Combination as Potential Cancer Treatment
2015-11-03 12:58:00| Merck.com - Product News
Dateline City: LONDON & KENILWORTH, N.J. Phase I first-in-human study to evaluate GSKs OX40 agonist GSK3174998 as monotherapy and in combination with Mercks anti-PD-1 therapy, KEYTRUDA (pembrolizumab) LONDON & KENILWORTH, N.J.--(BUSINESS WIRE)--GSK and Merck, known as MSD outside the US and Canada, today announced the initiation of a phase I clinical trial designed to evaluate GSKs investigational immunotherapy GSK3174998 as monotherapy and in combination with Mercks anti-PD-1 therapy, KEYTRUDA (pembrolizumab) in patients with locally advanced, recurrent or metastatic solid tumour(s) that have progressed after standard treatment. Language: English Contact: MerckMedia Relations:Pamela Eisele, +1 267-305-3558orAn Phan, +1 908-255-6325orInvestor Relations:Justin Holko, +1 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: study
potential
treatment
combination
Sites : [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] next »